Clearside Biomedical Management
Management criteria checks 1/4
Clearside Biomedical's CEO is George Lasezkay, appointed in Apr 2019, has a tenure of 5.08 years. total yearly compensation is $1.54M, comprised of 35.6% salary and 64.4% bonuses, including company stock and options. directly owns 0.51% of the company’s shares, worth $505.25K. The average tenure of the management team and the board of directors is 1.9 years and 4.9 years respectively.
Key information
George Lasezkay
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 35.6% |
| CEO tenure | 5.1yrs |
| CEO ownership | 0.5% |
| Management average tenure | 1.9yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
Nov 06
We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate
Jun 24Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
Nov 12Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)
Aug 11Clearside Biomedical Q2 2022 Earnings Preview
Aug 08Clearside Biomedical: A Pivotal 2022 Ahead
Apr 13Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play
Dec 22Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business
Sep 30Clearside's Value Proposition Is Far From Clear
Aug 07We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth
Jun 17Clearside Biomedical climbs after positive results from early-stage wet AMD trial
Jun 15Clearside Biomedical resubmits eye treatment XIPERE NDA
May 03If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns
Feb 16Clearside Biomedical's early-stage wet AMD study gets underway
Jan 12Trade Alert: Bradford Whitmore At Clearside Biomedical, Inc. (NASDAQ:CLSD), Has Just Spent US$1m Buying 11% More Shares
Jan 12Clearside Bio drops 11% on launch of $12M direct offering
Jan 06Clearside Biomedical: SCS Microinjector Platform With Significant Upside
Jan 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$35m |
| Dec 31 2023 | US$2m | US$547k | -US$32m |
| Sep 30 2023 | n/a | n/a | -US$37m |
| Jun 30 2023 | n/a | n/a | -US$36m |
| Mar 31 2023 | n/a | n/a | -US$35m |
| Dec 31 2022 | US$2m | US$532k | -US$33m |
| Sep 30 2022 | n/a | n/a | -US$5m |
| Jun 30 2022 | n/a | n/a | -US$2m |
| Mar 31 2022 | n/a | n/a | US$83k |
| Dec 31 2021 | US$2m | US$516k | US$376k |
| Sep 30 2021 | n/a | n/a | -US$25m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$23m |
| Dec 31 2020 | US$1m | US$503k | -US$18m |
| Sep 30 2020 | n/a | n/a | -US$14m |
| Jun 30 2020 | n/a | n/a | -US$18m |
| Mar 31 2020 | n/a | n/a | -US$18m |
| Dec 31 2019 | US$1m | US$385k | -US$31m |
| Sep 30 2019 | n/a | n/a | -US$49m |
| Jun 30 2019 | n/a | n/a | -US$67m |
| Mar 31 2019 | n/a | n/a | -US$82m |
| Dec 31 2018 | US$150k | n/a | -US$83m |
| Sep 30 2018 | n/a | n/a | -US$78m |
| Jun 30 2018 | n/a | n/a | -US$72m |
| Mar 31 2018 | n/a | n/a | -US$65m |
| Dec 31 2017 | US$167k | n/a | -US$59m |
Compensation vs Market: George's total compensation ($USD1.54M) is above average for companies of similar size in the US market ($USD663.45K).
Compensation vs Earnings: George's compensation has increased whilst the company is unprofitable.
CEO
George Lasezkay (71 yo)
5.1yrs
Tenure
US$1,538,627
Compensation
Dr. George M. Lasezkay, Pharm D, & J.D. has been Chief Executive Officer at Clearside BioMedical, Inc. since March 2020, serves as President since March 1, 2020 and served as its Interim Chief Executive Of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.1yrs | US$1.54m | 0.51% $ 505.3k | |
| Chief Financial Officer | 12.3yrs | US$854.41k | 0.45% $ 445.4k | |
| Chairman of Scientific Advisory Board | 5.6yrs | US$749.87k | 0% $ 0 | |
| Head of Investor Relations | no data | no data | no data | |
| Senior Vice President of Corporate Development & Alliance Management | 1.7yrs | no data | no data | |
| Senior Vice President of Engineering & Manufacturing | 1.3yrs | no data | no data | |
| Chief Clinical Officer | 1.9yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | 0.040% $ 39.6k | |
| Secretary | no data | no data | no data |
1.9yrs
Average Tenure
58yo
Average Age
Experienced Management: CLSD's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.8yrs | US$1.54m | 0.51% $ 505.3k | |
| Chairman of Scientific Advisory Board | 1.3yrs | US$749.87k | 0% $ 0 | |
| Independent Director | 12.3yrs | US$86.08k | 0.0059% $ 5.8k | |
| Independent Director | 2.2yrs | US$88.58k | 0.014% $ 13.4k | |
| Independent Director | 5.7yrs | US$88.58k | 0% $ 0 | |
| Independent Chair of the Board | 12.3yrs | US$96.08k | 0.054% $ 53.5k | |
| Member of Scientific Advisory Board | 4.1yrs | no data | no data | |
| Independent Director | 12.3yrs | US$91.71k | 0.068% $ 67.4k | |
| Member of Scientific Advisory Board | 4.1yrs | no data | no data | |
| Independent Director | 4.1yrs | US$85.46k | 0.12% $ 122.8k | |
| Independent Director | 8.3yrs | US$91.08k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.1yrs | no data | no data |
4.9yrs
Average Tenure
62yo
Average Age
Experienced Board: CLSD's board of directors are considered experienced (4.9 years average tenure).